Synbio Technologies and GSL Biotech have finalized a non-exclusive agreement allowing customers of GSL Biotech’s “SnapGene” software to order constructs directly from Synbio Technologies after having designed them in SnapGene.

On November 7th 2017, Synbio Technologies is excited to be publicly listed on the NEEQ and we are eager to observe the benefits this listing brings.

Synbio Technologies has recently made a break through in synthetic biology through use of synthetic DNA libraries.

Synbio Technologies has unlocked a paradigm shift in the way modern scientists approach DNA synthesis.

Synbio Technologies has recently developed a mechanism of DNA synthesis which may alter synthetic biology as we know it.

Synbio Technologies has recently made a break through in synthetic biology through use of sgRNA libraries.

Fusion Antibodies Ltd (UK) and Synbio Technologies Co. Ltd (China/USA) are excited to announce a commercial partnership to support biologic drug development in China.

Synbio Technologies, a leading international synthetic biology service company, recently announced a new partnership with ALSTEM, LLC, a United States biotech company, with the aim of developing various human CRISPR-Cas9 sgRNA libraries.

Synbio Technologies will attend the 13th annual Essential Protein Engineering Summit (PEGS), May 1-5, 2017, at the Seaport World Trade Center in Boston, Massachusetts.

Twist Bioscience, a high-quality DNA synthesis company, announced that it signed an agreement with Synbio Technologies. The companies will partner their respective capabilities to provide customers with access to long-length genes up to 70 kilobases.